Mesoblast (MESO) - Investor Forum at the World Stem Cell Summit
Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platforms, remestemcel-L and rexlemestrocel-L, to establish a broad portfolio of late-stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2040 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Rexlemestrocel-L is being developed for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
Presenter: Dr. Silviu Itescu
Видео Mesoblast (MESO) - Investor Forum at the World Stem Cell Summit канала channelchek
Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2040 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Rexlemestrocel-L is being developed for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
Presenter: Dr. Silviu Itescu
Видео Mesoblast (MESO) - Investor Forum at the World Stem Cell Summit канала channelchek
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Tesla's Dojo Supercomputer: A $600 Billion OpportunityRipple (XRP) vs. SEC RulingMaple Gold Mines (MGMLF) Scheduled to Present at NobleCon18 Investor ConferenceAvino Silver & Gold Mines (ASM) Scheduled to Present at NobleCon18 Investor ConferenceMeta Materials (MMAT) NobleCon18 Presentation ReplayGenprex (GNPX) NobleCon18 Presentation ReplayWelcome to ChannelchekVirtual Roadshow with TAAL Distributed Information Technologies (TAALF) President Chris NaprawaVox Royalty Corp. (VOXCF) Scheduled to Present at NobleCon18 Investor ConferenceStandard Uranium (STTDF)(STND.V) - Uranium Power Players Investor ForumVirtual Roadshow with Schwazze (SHWZ) CEO Justin Dye & CFO Nancy HuberInPlay Oil (IPOOF) NobleCon18 Presentation ReplaySQL Technologies (SKYX) NobleCon18 Presentation ReplayLithiumBank Resources (LBNKF)(LBNK) CEO Robert Shewchuk - C-Suite Interview SeriesThe World Is HOT Right Now! A Look at Global Economics Since COVID-19 -NobleCon18 Panel PresentationCommercial Vehicle Group (CVGI) CEO Harold Bevis & CFO Andy Cheung - C-Suite Interview SeriesEndeavour Silver Forsees 15 Million Ounces of Silver ProductionFLYHT Aerospace Solutions (FLYLF) CEO Bill Tempany & CFO Alana Forbes – Presentation from NobleCon17What Does the July Fed Pause Mean?Virtual Roadshow with Driven By Stem (STMH) CEO Adam BerkAtossa Therapeutics CEO Discusses Breast Density Data - Noble Capital Markets Healthcare Conference